{
    "clinical_study": {
        "@rank": "154533", 
        "acronym": "FSGS", 
        "arm_group": [
            {
                "arm_group_label": "fresolimumab 1 mg/kg total body weight", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "fresolimumab 4 mg/kg total body weight", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of this trial are as follows:\n\n        -  to compare the achievement of a partial remission (PR) or complete remission (CR) in\n           urinary protein: creatinine ratio (Up/c ratio) in patients treated with fresolimumab\n           versus placebo\n\n        -  to compare the safety profile of patients treated with fresolimumab versus placebo\n\n      The secondary objectives are as follows:\n\n        -  To compare the reduction in proteinuria in patients treated with fresolimumab versus\n           placebo\n\n        -  To evaluate fresolimumab dose-dependent reduction in proteinuria\n\n        -  To compare the change in renal function (estimated glomerular filtration rate [eGFR])\n           in patients treated with fresolimumab versus placebo\n\n        -  To evaluate the multiple-dose pharmacokinetics of fresolimumab"
        }, 
        "brief_title": "A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Focal Segmental Glomerulosclerosis", 
        "condition_browse": {
            "mesh_term": "Glomerulosclerosis, Focal Segmental"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient's renal biopsy is consistent with the diagnosis of primary Focal\n             Segmental Glomerulosclerosis (FSGS) including all histological subtypes.\n\n          -  The patient has an eGFR \u2265 30 mL/min/1.73 m2\n\n          -  The patient has a urinary total protein:creatinine ratio \u2265 3 mg protein/mg creatinine\n\n          -  In the opinion of the Investigator, the patient has steroid-resistant FSGS. The\n             patient must have been treated for FSGS with a course of high-dose steroid therapy\n             for a minimum of 4 weeks\n\n          -  The patient has been treated with an ACEi (angiotensin converting enzyme inhibitor)\n             and/or ARB (angiotensin receptor blocker) at a stable dose for a minimum of 4 weeks\n             prior to Visit 2 (treatment start)\n\n        Exclusion Criteria:\n\n          -  The patient has FSGS which in the Investigator's opinion is secondary to another\n             condition\n\n          -  The patient has been taking prednisone at a dose > 10 mg/day (or equivalent dose of\n             an alternative glucocorticoid) within 4 weeks prior to Visit 1 (Screening Visit).\n\n          -  The patient has received any other systemically administered immunosuppressive drugs\n             (other than glucocorticoids) within 8 weeks prior to Visit 1.\n\n          -  The patient has received rituximab within 6 months prior to Visit 1.\n\n          -  The patient has a history of organ transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665391", 
            "org_study_id": "GC1008FSGS03110", 
            "secondary_id": [
                "2010-019545-25", 
                "U1111-1139-9082"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "fresolimumab 1 mg/kg total body weight", 
                "description": "1 mg/kg total body weight administered intravenous (IV)", 
                "intervention_name": "fresolimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "fresolimumab 4 mg/kg total body weight", 
                "description": "4 mg/kg total body weight administered intravenous (IV)", 
                "intervention_name": "fresolimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered to match active treatment group", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35205"
                    }, 
                    "name": "Investigational Site Number 4008"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85032"
                    }, 
                    "name": "Investigational Site Number 4029"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Investigational Site Number 4009"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Investigational Site Number 4023"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Investigational Site Number 4005"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "01107"
                    }, 
                    "name": "Investigational Site Number 4019"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Investigational Site Number 4004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "Investigational Site Number 4002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Investigational Site Number 4022"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Investigational Site Number 4012"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Investigational Site Number 4025"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Investigational Site Number 4006"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Investigational Site Number 4024"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Investigational Site Number 4003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Investigational Site Number 4016"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosedale", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11422"
                    }, 
                    "name": "Investigational Site Number 4014"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Investigational Site Number 4018"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Investigational Site Number 4001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "Investigational Site Number 4020"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Investigational Site Number 4027"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195"
                    }, 
                    "name": "Investigational Site Number 4013"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "zip": "90035 003"
                    }, 
                    "name": "Investigational Site Number 4104"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "52074"
                    }, 
                    "name": "Investigational Site Number 4302"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40225"
                    }, 
                    "name": "Investigational Site Number 4301"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }, 
                    "name": "Investigational Site Number 4304"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "zip": "70124"
                    }, 
                    "name": "Investigational Site Number 4401"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "zip": "24127"
                    }, 
                    "name": "Investigational Site Number 4404"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montichiari", 
                        "country": "Italy", 
                        "zip": "25018"
                    }, 
                    "name": "Investigational Site Number 4403"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Calabria", 
                        "country": "Italy", 
                        "zip": "89124"
                    }, 
                    "name": "Investigational Site Number 4405"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Investigational Site Number 4503"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Investigational Site Number 4504"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Investigational Site Number 4502"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Brazil", 
                "Germany", 
                "Italy", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis", 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Ministry of Health", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of patients achieving partial remission (PR) or complete remission (CR) in urinary protein: creatinine ratio (Up/c ratio)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Number of patients reporting adverse events (AEs), serious adverse events (SAEs), and medical events of interest (MEOIs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 112"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665391"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients achieving CR in Up/c ratio", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Percentage of patients achieving PR in Up/c ratio", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Change from baseline in Up/c ratio and urinary protein excretion rate", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Time to first PR or CR", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Change from baseline in eGFR (estimated glomerular filtration rate)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Percentage of patients achieving PR or CR with stable eGFR (estimated glomerular filtration rate)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 112"
            }, 
            {
                "measure": "Pharmacokinetics as measured by Cmax, tmax, AUC (area under curve) 0-last, C trough, t 1/2z", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 252"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}